Skip to search formSkip to main contentSkip to account menu

VTX-2337

Known as: TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337 
A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Benzazepines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
In vitro metabolic profiles of motolimod by using liquid chromatography tandem mass spectrometry: Metabolic stability, metabolite characterization and species comparison
2015
2015
A phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC).
TPS3092 Background: HNC is an immunosuppressive disease, with low absolute lymphocyte counts, impaired activity of effector cells… 
2014
2014
Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head…
TPS3123 Background: The potential for synergy between cytotoxic and immunologic agents is an exciting area of exploration in… 
2014
2014
Advanced Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiation Therapy
2014
2014
Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)
2013
2013
VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: Preclinical and phase I data by the Gynecologic Oncology Group.
3077 Background: Given the absence of clear molecular drivers in high-grade serous ovarian cancer, targeting the tumor micro… 
2012
2012
Cancer Therapy : Preclinical VTX-2337 Is a Novel TLR 8 Agonist That Activates NK Cells and Augments ADCC
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its… 
2012
2012
Augments ADCC VTX-2337 Is a Novel TLR 8 Agonist That Activates NK Cells and Updated
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its… 
2011
2011
Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.
2537 Background: Toll-like receptors (TLRs) have emerged as attractive targets for anti-cancer immunotherapies. VTX-2337 is a… 
2011
2011
Abstract 4745: TLR8 agonist and Doxil chemotherapy potently activate human antitumor immune response in a human immune system mouse model
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Because of differences between mouse and human immune… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)